

Serial No.: 10/661,804

IN THE SPECIFICATION:

Please amend the specification as follows:

Please replace the paragraph beginning on page 1, line 4 of the subject application with the paragraph following:

Related Applications

This application is a continuation of PCT patent application number PCT/EP02/02671, filed March 12, 2002, which claims priority to ~~German~~ European patent application number 01106033.2, filed March 12, 2001, the disclosures of each of which are incorporated herein by reference in their entirety.

Please replace the paragraph beginning on page 4, line 25 of the subject application as filed with the paragraph following:

- (6) a method to identify, monitor and/or remove CD4<sup>+</sup>CD25<sup>+</sup> T cells from human blood and other tissues *ex vivo* or *in vivo*, which method comprises
- (i) utilizing agents/ligands specifically binding to the CD4, and/or CD25, and/or CTL-A4 (~~CD154~~) (CD152) entities on the T cells, preferably anti-CD4 and/or anti-CD25, and/or anti-CTL-A4 antibodies, and/or
  - (ii) utilizing immunoadsorption methods; and/or
  - (iii) utilizing a stimulating agent or antigen presenting cells as defined in (2) above;

Please replace the paragraph beginning on page 6, line 8 of the subject application as filed with the paragraph following:

- (14) use of agents specifically binding to the CD4 and/or CD25 and/or CTL-A4 (~~CD154~~) (CD152) entities on the T cells, including but not limited to ligands/antibodies, such as anti-CD25 and/or anti-CTL-A4 mAb, or antibodies or MHC-peptide complexes or other ligands binding to T cell receptors on (subsets of) CD4<sup>+</sup>CD25<sup>+</sup> T cells for preparing a medicament for removal or functional impairment of CD4<sup>+</sup>CD25<sup>+</sup> T cells *in vivo* in order to enhance immune responses, including

Serial No.: 10/661,804

dampen regulation by CD4<sup>+</sup>CD25<sup>+</sup> T cells *in vivo*, for example, to enhance tumor immunity.

Please replace the paragraph beginning on page 7, line 4 of the subject application as filed with the paragraph following:

(A) The phenotypical characterization of the human CD4<sup>+</sup>CD25<sup>+</sup> T cells now allows the identification, monitoring (e.g. by FACS), isolation and removal of these cells from human blood and other tissues *ex vivo* (hereinafter occasionally referred to as "*in vitro*") or *in vivo*. This isolation or removal can be achieved by contacting the human blood or other tissues with suitable agents *ex vivo*. Suitable agents are in particular anti-CD4, anti-CD25, anti-CTL-A4 (~~CD154~~) (CD152) antibodies, etc.

Please replace the paragraph beginning on page 10, line 4 of the subject application as filed with the paragraph following:

(G) The agents specifically binding to the CD4 and/or CD25 and/or CTL-A4 (~~CD154~~) (CD152) entities on the T cells as defined in (14) above can be used to remove and to monitor removal of CD4<sup>+</sup>CD25<sup>+</sup> T cells *in vivo* e.g. by anti-CD25 and/or anti-CTL-A4 mAb (unmodified or modified e.g. conjugated to toxins) or by immunoadsorption (blood is flowing through columns and CD4<sup>+</sup>CD25<sup>+</sup> T cells are removed by solid phase-bound antibodies directed to molecules expressed on the surface of CD4<sup>+</sup>CD25<sup>+</sup> T cells e.g. anti-CD25) in order to enhance immune responses, e.g. dampen regulation by CD4<sup>+</sup>CD25<sup>+</sup> T cells *in vivo*, for example, to enhance tumor immunity.